Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
424studies shown
Showing 126-150 of 424
RecruitingNCT07003529

Role of Inferior Colliculi in Auditory Hallucinations

This study is looking at care and outcomes for people with Schizophrenia or Hallucinations, Auditory. Some participants may receive Control Group (SCZ+/AH-) instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nīmes
Condition
Schizophrenia
Not Yet RecruitingNCT07266376

Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS

This study is comparing Integrative group therapy with Media-workshop control group for people with Mental Disorder or Schizophrenia Diagnosis. Participants receive Integrative group therapy or Media-workshop control group and complete study visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Condition
Schizophrenia
RecruitingNCT06634641

Clozapine-related Immunodeficiency in Parkinsons Disease

This study is looking at whether blood test can help people with psychosis. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire, Amiens
Condition
Schizophrenia
Not Yet RecruitingNCT06464848

Narrative Identity and Its Relationship to Subjective Multidimensional Well-being in First Episode Psychosis

This study is looking at focus on the acquisition of narrative identity in First Episode Psychosis (FEP) and its impact on multidimensional subjective well-being. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherOver 16 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire de Nīmes
Condition
Schizophrenia
Not Yet RecruitingNCT06817980

Disorders of the Sense of Self and Physical Activity

This study is looking at care and outcomes for people with SCHIZOPHRENIA 1, Borderline Personality Disorder, or Vestibular Syndromes. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
RecruitingNCT03649581

Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders

This study is looking at compare two subforms of psychotic disorders that have been clinically distinguished in the 1970s for people with Schizophrenia. Taking part may give some people access to compare the two groups of schizophrenic patients, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
RecruitingNCT05550155

Efficacy of Maintenance Repetitive Transcranial Magnetic Stimulation (rTMS) in Auditory Verbal Hallucinations

This study is looking at whether Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment can help people with Schizophrenia or Psychosis. Participants take part in Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment and complete follow-up assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France
Sponsor
University Hospital, Caen
Condition
Schizophrenia
RecruitingNCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07029581

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

This study is looking at care and outcomes for people with Lewy Body Dementia Psychosis. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 84 Years
Countries
Bulgaria, Czech Republic, France, Italy, Serbia, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
RecruitingNCT05511363

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Bulgaria, Croatia, Czech Republic, France, Germany, Italy, Serbia, Slovakia, Spain, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

This observational study is following people with Alzheimer's Disease Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 55 Years to 95 Years
Countries
Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Enrolling By InvitationNCT06194799

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

This study is looking at care and outcomes for people with Alzheimer's Disease Psychosis. Taking part may give some people access to ACP-204, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 95 Years
Countries
Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
RecruitingNCT05865652

Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition

This observational study is following people with With Ultra High Risk of Psychotic Transition to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

SchizophreniaOtherFrom 15 Years to 25 Years
Countries
France
Sponsor
Centre Hospitalier Henri Laborit
Condition
Schizophrenia
Active Not RecruitingNCT06539611

Prospective Cohort Study of a Population at Risk of Psychotic Transition

This observational study is following people with At-risk Mental States to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 15 Years to 30 Years
Countries
France
Sponsor
Centre Hospitalier Esquirol
Condition
Schizophrenia
RecruitingNCT07439276

Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery

This observational study is following people with Neurodevelopmental Disorders, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, or Atypical Neurodevelopmental Disorder to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

ADHDOtherFrom 8 Years to 16 Years
Countries
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Condition
ADHD